Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.
"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Light Tanks, Developed In 2 Years, Unveiled. Will Be Deployed Against China DRDO To Test Shoulder-Fired Air Defence Missiles At High-Altitudes Centre Extends Tenure Of Top Defence Scientist By One Year UP BJP Chief Tells PM He Wants To Quit, Amit Shah In Action Amid Rejig Buzz "I Divorce You... Your Ex-Wife": Dubai Princess Dumps Husband In Insta Post In Massive Row Over Karnataka 100% Quota Bill, Chief Minister Deletes Post Are Doors Still Open For Nephew Ajit? Sharad Pawar Said This Karnataka High Court Gives Bail To 3 Murder Accused In Gauri Lankesh Case Consumption, Private Investment: The Twin Challenge For Budget FY25 Track Latest News Live on NDTV.com and get news updates from India and around the world.